Security Snapshot

Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) Institutional Ownership

CUSIP: 877619106

13F Institutional Holders and Ownership History from Q3 2020 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

194

Shares (Excl. Options)

269,008,807

Price

$5.50

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.00001 per share
Symbol
TSHA on Nasdaq
Shares outstanding
275,000,000
Price per share
$4.47
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
269,008,807
Total reported value
$1,479,385,784
% of total 13F portfolios
0%
Share change
+6,395,054
Value change
+$50,473,906
Number of holders
194
Price from insider filings
$4.47
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • TSHA - Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share is tracked under CUSIP 877619106.
  • 194 institutions reported positions in Q4 2025.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 194 to 14 between Q4 2025 and Q1 2026.
  • Reported value moved from $1,479,385,784 to $10,594,523.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 194 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 877619106?
CUSIP 877619106 identifies TSHA - Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $90,456,313 +$7,574,932 27,662,481 +9.1% RA Capital Management, L.P. 30 Sep 2025
Manning Paul B 9.8% $59,394,578 25,601,111 Paul B Manning 30 May 2025
RTW INVESTMENTS, LP 8.3% -16% $120,312,664 -$9,129,432 23,407,133 -7.1% RTW Investments, LP 31 Dec 2025
BlackRock, Inc. 6.5% +26% $98,187,600 +$25,844,308 17,852,291 +36% BlackRock, Inc. 31 Dec 2025
MORGAN STANLEY 6.7% -21% $44,506,820 -$2,034,437 16,858,644 -4.4% Morgan Stanley 30 Jun 2025
Vestal Point Capital, LP 5% $70,675,000 13,750,000 Vestal Point Capital, LP 31 Dec 2025
FMR LLC 4.9% -22% $74,406,012 -$11,547,008 13,528,366 -13% FMR LLC 31 Dec 2025
GOLDMAN SACHS GROUP INC 5.1% $33,274,806 12,748,968 THE GOLDMAN SACHS GROUP, INC. 26 Jun 2025
Octagon Capital Advisors LP 3.3% -36% $29,650,725 -$4,520,775 9,067,500 -13% Octagon Capital Advisors LP 30 Sep 2025

As of 31 Dec 2025, 194 institutional investors reported holding 269,008,807 shares of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA). This represents 98% of the company’s total 275,000,000 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) together control 84% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 8.6% 23,555,648 0% 1.3% $129,556,064
Avoro Capital Advisors LLC 7.9% 21,700,000 0% 1.2% $119,350,000
BlackRock, Inc. 6.8% 18,643,129 +14% 0% $102,537,212
MORGAN STANLEY 6.6% 18,078,518 -6.4% 0.01% $99,431,850
RTW INVESTMENTS, LP 6% 16,398,297 -33% 0.9% $90,190,634
Vestal Point Capital, LP 5% 13,750,000 +150% 2.8% $75,625,000
GOLDMAN SACHS GROUP INC 5% 13,692,739 +2.3% 0.01% $75,310,065
FMR LLC 4.9% 13,528,366 -7.3% 0% $74,406,012
VANGUARD GROUP INC 4.8% 13,267,805 +3.3% 0% $72,972,929
STATE STREET CORP 3.9% 10,790,084 +49% 0% $59,345,462
Siren, L.L.C. 3.7% 10,129,913 -8% 1.7% $55,714,522
Octagon Capital Advisors LP 3.2% 8,859,911 -2.3% 6.1% $48,729,511
Polar Capital Holdings Plc 2.9% 7,931,403 +50% 0.2% $43,622,717
BARCLAYS PLC 2% 5,539,001 +7.6% 0.01% $30,464,506
GEODE CAPITAL MANAGEMENT, LLC 2% 5,387,026 +4.1% 0% $29,633,569
D. E. Shaw & Co., Inc. 1.5% 4,013,635 +48% 0.02% $22,074,993
BAKER BROS. ADVISORS LP 1.5% 4,004,756 0% 0.13% $22,026,158
Point72 Asset Management, L.P. 1.4% 3,868,682 -47% 0.03% $21,277,751
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 1.4% 3,722,000 0.03% $20,471,000
Affinity Asset Advisors, LLC 1.2% 3,300,000 +10% 1.3% $18,150,000
MILLENNIUM MANAGEMENT LLC 1.2% 3,178,863 -21% 0.01% $17,483,746
DEERFIELD MANAGEMENT COMPANY, L.P. 0.99% 2,722,165 -49% 0.19% $14,971,908
ADAR1 Capital Management, LLC 0.91% 2,495,809 -12% 1% $13,726,950
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.69% 1,902,978 +3.1% 0% $10,466,379
CITADEL ADVISORS LLC 0.67% 1,854,855 +405% 0.01% $10,201,703

Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 2,371,760 $10,594,523 +$6,181,120 $4.47 14
2025 Q4 269,008,807 $1,479,385,784 +$50,473,906 $5.50 194
2025 Q3 264,455,712 $864,768,038 +$29,349,082 $3.27 152
2025 Q2 257,684,976 $595,324,582 +$211,768,578 $2.31 147
2025 Q1 166,761,354 $231,855,383 -$5,171,826 $1.39 124
2024 Q4 167,381,791 $289,604,775 +$18,983,312 $1.73 126
2024 Q3 156,893,147 $315,365,141 -$17,620,277 $2.01 114
2024 Q2 158,086,076 $354,139,573 +$33,881,138 $2.24 102
2024 Q1 140,148,555 $402,080,424 +$33,453,660 $2.87 106
2023 Q4 130,129,882 $230,288,972 -$12,329,934 $1.77 85
2023 Q3 129,862,060 $410,364,849 +$376,246,041 $3.16 59
2023 Q2 13,698,356 $9,051,371 -$2,014,707 $0.66 37
2023 Q1 16,687,605 $13,286,354 -$3,025,814 $0.80 42
2022 Q4 19,375,255 $43,785,515 +$12,385,904 $2.26 51
2022 Q3 13,927,007 $27,020,000 -$1,811,564 $1.93 48
2022 Q2 14,700,530 $54,695,000 -$11,594,670 $3.72 55
2022 Q1 17,015,055 $110,894,239 -$16,224,000 $6.52 70
2021 Q4 18,503,286 $215,562,592 -$15,412,583 $11.65 64
2021 Q3 19,436,846 $361,910,267 +$4,396,852 $18.62 48
2021 Q2 18,320,557 $388,394,891 +$15,022,269 $21.20 48
2021 Q1 17,661,042 $358,518,075 -$11,587,017 $20.30 46
2020 Q4 17,998,551 $475,216,635 +$32,037,839 $26.54 51
2020 Q3 16,580,732 $366,712,000 +$366,712,000 $22.40 46